{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T19:33:03Z","timestamp":1771788783595,"version":"3.50.1"},"reference-count":38,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.2967\/jnumed.112.115170","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T03:29:53Z","timestamp":1365564593000},"page":"1045-1052","source":"Crossref","is-referenced-by-count":52,"title":["Radioimmunotherapy with <sup>177<\/sup>Lu-DOTA-Rituximab: Final Results of a Phase I\/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas"],"prefix":"10.2967","volume":"54","author":[{"given":"Flavio","family":"Forrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina","family":"Oechslin-Oberholzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Campana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut R.","family":"Maecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Mueller-Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Lohri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2013,4,9]]},"reference":[{"key":"2021051712045841000_54.7.1045.1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200101000-00001"},{"key":"2021051712045841000_54.7.1045.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"issue":"4, suppl 6","key":"2021051712045841000_54.7.1045.3","first-page":"15","article-title":"Antibody-targeted therapy for low-grade lymphoma","volume":"36","author":"Vose","year":"1999","journal-title":"Semin Hematol."},{"issue":"3, suppl","key":"2021051712045841000_54.7.1045.4","first-page":"1014s","article-title":"Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1","volume":"50","author":"DeNardo","year":"1990","journal-title":"Cancer Res."},{"key":"2021051712045841000_54.7.1045.5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.1991.9.4.548","article-title":"Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody","volume":"9","author":"Goldenberg","year":"1991","journal-title":"J Clin Oncol."},{"key":"2021051712045841000_54.7.1045.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"2021051712045841000_54.7.1045.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"issue":"10, suppl","key":"2021051712045841000_54.7.1045.8","first-page":"3281s","article-title":"Radioimmunotherapy of relapsed non-Hodgkin\u2019s lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody","volume":"5","author":"Wiseman","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2021051712045841000_54.7.1045.9","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000276"},{"key":"2021051712045841000_54.7.1045.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2021051712045841000_54.7.1045.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.043"},{"key":"2021051712045841000_54.7.1045.12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1040-8428(01)00108-1","article-title":"The role of radiolabeled antibodies in the treatment of non-Hodgkin\u2019s lymphoma: the coming of age of radioimmunotherapy","volume":"39","author":"Goldenberg","year":"2001","journal-title":"Crit Rev Oncol Hematol."},{"key":"2021051712045841000_54.7.1045.13","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol."},{"key":"2021051712045841000_54.7.1045.14","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2.5.485"},{"key":"2021051712045841000_54.7.1045.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"2021051712045841000_54.7.1045.16","doi-asserted-by":"publisher","DOI":"10.1080\/028418601750444141"},{"key":"2021051712045841000_54.7.1045.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01663-7"},{"key":"2021051712045841000_54.7.1045.18","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100570"},{"key":"2021051712045841000_54.7.1045.19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.5858\/2000-124-0921-HAMA","article-title":"Human anti-mouse antibodies","volume":"124","author":"Klee","year":"2000","journal-title":"Arch Pathol Lab Med."},{"key":"2021051712045841000_54.7.1045.20","first-page":"879","article-title":"Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy","volume":"45","author":"Schroff","year":"1985","journal-title":"Cancer Res."},{"key":"2021051712045841000_54.7.1045.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3470"},{"key":"2021051712045841000_54.7.1045.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269753"},{"key":"2021051712045841000_54.7.1045.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1120-2"},{"key":"2021051712045841000_54.7.1045.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.891"},{"key":"2021051712045841000_54.7.1045.25","unstructured":"National Cancer Institute Web site. Common terminology criteria for adverse events v3.0 (CTCAE). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Published August 9, 2006. Accessed March 27, 2013."},{"key":"2021051712045841000_54.7.1045.26","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050462"},{"key":"2021051712045841000_54.7.1045.27","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin\u2019s lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol."},{"key":"2021051712045841000_54.7.1045.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"2021051712045841000_54.7.1045.29","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res."},{"key":"2021051712045841000_54.7.1045.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4690"},{"key":"2021051712045841000_54.7.1045.31","doi-asserted-by":"crossref","unstructured":"Kaminski MS Tuck M Estes J . Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results [abstract]. Blood. 2009;114(suppl): abstract 3759.","DOI":"10.1182\/blood.V114.22.3759.3759"},{"key":"2021051712045841000_54.7.1045.32","doi-asserted-by":"crossref","unstructured":"Hagenbeek A Radford J Van Hoof A . 90Y-ibritumomab tiuxetan (Zevalin\u00ae) consolidation of first remission in advanced-stage follicular non-Hodgkin\u2019s lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized, phase III first-line indolent trial (FIT) in 414 patients [abstract]. Blood. 2010;116(suppl): abstract 594.","DOI":"10.1182\/blood.V116.21.594.594"},{"key":"2021051712045841000_54.7.1045.33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi320"},{"key":"2021051712045841000_54.7.1045.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8545"},{"key":"2021051712045841000_54.7.1045.35","doi-asserted-by":"crossref","unstructured":"Smith MR Zhang L Gordon LI . Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499 [abstract]. Blood. 2009;110(suppl): abstract 389.","DOI":"10.1182\/blood.V110.11.389.389"},{"key":"2021051712045841000_54.7.1045.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"2021051712045841000_54.7.1045.37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9217"},{"key":"2021051712045841000_54.7.1045.38","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.112.115170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T19:48:16Z","timestamp":1621280896000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.112.115170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,9]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,1]]},"published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.2967\/jnumed.112.115170"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.112.115170","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,9]]}}}